Upon substrate binding TG2 dramatically changes its structure (Pinkas et al., PLoS Biol. 2007). By reacting TG2 with a novel irreversible inhibitor we could stabilize TG2 in the open conformation which we branded Open tTG™.

Open tTG™ – it fits the antigen to the autoantibody – is the key to detect seronegative or borderline celiac disease patients. Used as antigen in ELISA-based diagnostics, Open tTG™ (E006/E007) is superior to the so far used closed conformation TG2 especially for patient's sera with low or negative tTG autoantibody-titers (Lindfors et al., J. Clin. Immunol. 2011, 31:436-42).

For the purified non coated protein products
Open tTGTM, Inhibited TG3 and Inhibited TG6 please refer to Section: Transglutaminases

Art. No.
E006 ZediXclusive Open tTGTM-ab ELISA (IgA)
Open tTGTM tissue transglutaminase (TG2) ELISA Kit (IgA)
1 kit/96 wells
520 €
E007 ZediXclusive Open tTGTM-ab ELISA (IgG)
Open tTGTM tissue transglutaminase (TG2) ELISA Kit (IgG)
1 kit/96 wells
520 €


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation




    13.11.2017 - 16.11.2017
    Düsseldorf, Germany

  • Gordon Research Conference on: Transglutaminases in Human Disease Processes

    16.06.2018 - 17.06.2018
    Les Diablerets, Switzerland